SCHEDULE: Trigran Investments Discloses 1.2% Stake in Anika Therapeutics

Trigran Investments and its principals have filed an amended Schedule 13G, reporting a 1.2% beneficial ownership stake in Anika Therapeutics, Inc. as of December 31, 2025.

Summary

• Trigran Investments, Inc. and its principals (Douglas T. Granat, Lawrence A. Oberman, Steven G. Simon, Bradley F. Simon, and Steven R. Monieson) collectively beneficially own 168,400 shares of Anika Therapeutics, Inc. common stock.
• This ownership represents 1.2% of Anika Therapeutics, Inc.'s outstanding common stock.
• The reporting persons hold shared voting power over 124,358 shares and shared dispositive power over 168,400 shares.
• The shares were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of the issuer, except for activities solely in connection with a nomination under Rule 14a-11.
• The reporting persons disclaim beneficial ownership of the reported shares, except to the extent of their pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral. This is a routine disclosure of passive ownership and does not contain information that would significantly alter the investment thesis for Anika Therapeutics. It simply confirms an existing institutional stake.

Positives

• A notable institutional investor, Trigran Investments, maintains a position in Anika Therapeutics, indicating continued interest in the company.

Negatives

• The filing does not indicate any new significant increase in investment or activist intent that would signal a strong new vote of confidence or potential for corporate change.

Risks

• The reporting persons explicitly state that their holdings are not for the purpose of changing or influencing control, indicating they are passive investors and are unlikely to drive significant corporate or strategic changes.

Future Outlook

This filing is a routine disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Anika Therapeutics' future performance or strategic direction.

Management Comments

• "The Reporting Person disclaims beneficial ownership of the shares reported in this Schedule 13G, except to the extent of its pecuniary interest."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a standard regulatory disclosure of passive institutional ownership in a publicly traded company within the healthcare sector. It does not provide specific insights into broader industry trends or competitive dynamics beyond confirming an investor's stake in Anika Therapeutics.

Comparison to Industry Standards

• The 1.2% stake held by Trigran Investments is a relatively small passive position for an institutional investor, which is typical for a Schedule 13G filing, indicating a non-controlling interest.
• This filing contrasts with a Schedule 13D, which would be filed by an investor holding over 5% with an intent to influence management or control, signaling Trigran's passive investment strategy.

Stakeholder Impact

• Shareholders: Provides transparency regarding a passive institutional investor's stake, confirming a 1.2% ownership by Trigran Investments and its principals.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of a passive investment by Trigran Investments, Inc. and its principals, reporting a 1.2% stake in Anika Therapeutics. It does not indicate any new strategic moves, significant changes in company fundamentals, or activist intent. As such, it provides no new information to warrant a change in an existing investment position. Investors should continue to hold based on their existing analysis of Anika Therapeutics' operational and financial performance, rather than this ownership disclosure.

Keywords

Anika Therapeutics, Trigran Investments, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, Healthcare, Biotechnology